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ment of high-risk patients. J Thorac Cardiovasc Surg. 2012;143:78-84.MMENTARYPercutaneous edge-to-edge repair for degenerative mitral regurgitation:
A journey to the edge of the bell-shaped curvePatrick M. McCarthy, MDThe report in this issue of the Journal by Taramasso and
colleagues1 is a welcome addition, as most reports ofMitra-
Clip (Abbott Vascular, Santa Clara, Calif) outcomes have
been in the cardiology literature. Taramasso and col-
leagues1 report excellent outcomes in a high-risk surgical
population (78.5  10.8 years; 71% New York HeartAssociation functional class III or IV; mean Society of
Thoracic Surgeons [STS] score 12%  10%) with severe
degenerative mitral regurgitation (DMR). Their results
mirror the US MitraClip experience presented to the Food
and Drug Administration panel with a low procedural risk
(2% in-hospital mortality), low morbidity, no clip emboli-
zation, a very high procedural ‘‘success’’ rate (98%), and
short stay relative to conventional surgery.2 DMR
frequently is seen with an anatomically difficult lesion to
treat with the MitraClip; however, there was a reasonable
reduction in mitral regurgitation to grade II or less in
91.5% of patients. The 1-year survival (89%  5.2%),
New York Heart Association functional class (93% I or
II), and 6-minute walk (mean improvement of 48 meters)
were favorable. Initial trials in the United States included
low- and medium-risk patients, the type of patients in the
middle of the bell-shaped curve of patients treated with sur-
gery, and reflected a strategy (and hubris) to compete
directly with conventional heart surgery. These trials, prin-
cipally the Endovascular Valve Edge-to-Edge Repair High
Risk Study (EVEREST) and the continued access protocol,
took a long time to execute as the tactics evolved and the
target patient population shifted to the sickest patients ongery c December 2014
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A
C
Dthe edge of the bell-shaped curve. Ultimately, the clip can
improve DMR, but it does not reduce it as much as does
conventional mitral repair, so it was judged safe but less
effective. The Food and Drug Administration recently
approved MitraClip in the high-risk DMR population, and
multiple publications have reported favorable outcomes.3-5
So, just how far out on the curve are these MitraClip can-
didates? Taramasso and colleagues1 at San Rafaele provide
perspective. Their 48 patients with DMR were only 2% of
those treated (2370 patients) with surgical mitral valve
repair. Only 5.6% of patients undergoing mitral valve sur-
gery listed in the STS database have a score greater than
or equal to 12, and of these 85% underwent replacement,
not repair.2 Another 116 patients underwent MitraClip im-
plantation for functional mitral regurgitation, which is the
target population for the US Clinical Outcomes Assessment
of the MitraClip Therapy Percutaneous Therapy for Heart
Failure Patients With Functional Mitral Regurgitation
(COAPT) Trial.6 According to Taramasso and colleagues
(personal communication), although they did not track all
patients that were screened for theMitraClip, they estimated
that only 1 in 4were treated, and in only 4 of the 48was there
a commissural lesion. The STS database is an excellent tool
to risk stratify patients in the middle of the bell-shaped
curve; however, patients may have many unusual comorbid-
ities that are not collected by the STS database. These have
been described by the Valve Academic Research Con-
sortium7 and include such medical conditions as cirrhosis,
radiation heart disease, ‘‘hostile’’ chest, and extensive aortic
calcification or atherosclerosis. Some surgeons have rightly
been concerned that the MitraClip studies include patients
with a low STS score. As an example, however, 1 patient
presented to the Food and Drug Administration panel had
multiple sclerosis, was hemiplegic from a previous stroke,
and was assisted by a wheelchair yet had a calculated STS
score less than 2.2 The STS score cannot predict the likeli-
hood of good functional recovery. A reasonable concern is
that we may apply the MitraClip in patients whose condi-
tions are futile, and their quality of life will be so limited
that there is no meaningful improvement. The outcomes
from San Rafaele are reassuring, because quality of life
and New York Heart Association functional class improved
significantly for the majority of patients.
MitraClip is much safer than surgery for these very high-
risk patients, so will patient selection gradually migrate
back toward the center of the bell shaped curve, as trans-
catheter aortic valve replacement is evolving? It seemsThe Journal of Thoracic and Carunlikely in the near term and midterm. The surgical treat-
ment of DMR is one of the greatest success stories in car-
diac surgery, and as a result of stepwise improvements in
surgical techniques and care, we are now able to achieve
extremely low mortality and morbidity, a high rate of dura-
ble repair, and excellent functional outcomes.8 A host of
new technologies are now being developed to mimic mitral
valve repair or to perform transcatheter mitral valve
replacement; however, this is a formidable problem
compared with transcatheter aortic valve replacement.9
For the distinctive subset of patients with DMR, the risk-
to-benefit ratio for a new device to compete with mitral sur-
gery is not attractive, and functional mitral regurgitation is a
more practical target.
The value of this study is to acknowledge that this is an
option for patients on whom we would not want to operate.
It has achieved a reasonable degree of success for patients
who meet the anatomic criteria, the risks are low, and recov-
ery is quite good. As surgeons accumulate experience, we
will prepare for the emerging transcatheter approaches.References
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